Why pharma exports could be Pakistan’s next billion-dollar opportunity?
Pakistan’s pharmaceutical industry has been on an upward trajectory thanks to deregulation, margin expansion, and a rising domestic market. But a far less discussed, and...
Why GLAXO’s antibiotic portfolio is its greatest asset?
In Pakistan’s rapidly evolving pharmaceutical landscape, one drug category continues to reign supreme: antibiotics. Valued at approximately PKR 185 billion in FY25 and growing at...
5 Reasons AGP Limited Could Be Your Next Big Pharma Pick
As Pakistan's pharmaceutical sector evolves rapidly post-deregulation, AGP Limited (AGP) stands out as one of the most attractive investment opportunities. With a strong product mix,...
Pharma Stock Valuations Are at a Discount, Is Now the Time to Buy?
Pakistan’s pharmaceutical sector has quietly morphed into a compelling value play. Despite major regulatory relief, margin expansion, and earnings growth, valuations across the board remain...
How Policy Shifts and Demographics Are Reshaping Pakistan’s Drug Industry?
Pakistan’s pharmaceutical sector is undergoing a transformation. A combination of regulatory liberalization and long-term demographic trends is setting the stage for sustained growth, making it...
Can Pakistan’s local drugmakers outperform multinationals?
Pakistan’s pharmaceutical sector has entered a phase of structural transformation, and one question stands out: Can local drug manufacturers truly outperform multinational companies (MNCs)? Based...
Abbott’s comeback plan: why reintroduced drugs could boost future earnings?
Abbott Laboratories (Pakistan) Ltd, (ABOT) one of the country’s top multinational pharmaceutical players, is taking a bold step to reintroduce several previously discontinued products. This...
Is Haleon stock ready to soar on new Panadol variants?
In Pakistan’s evolving pharmaceutical landscape, few brands hold as dominant a position as Panadol. Now, Haleon Pakistan Ltd (HALEON) is doubling down on this flagship...